Efficacy and tolerability of celecoxib and naproxen versus placebo in Hispanic patients with knee osteoarthritis

International Journal of General Medicine

Volumn 7, Issue , 2014, Pages 227-235

  Essex, Margaret Noyes ^a   Behar, Regina ^a   O'Connell, Michael A ^a   Brown, Pritha Bhadra ^a  

^a PFIZER INC   (United States)

Author keywords

Cyclo oxygenase 2; Ethnicity; Nonsteroidal anti inflammatory drugs; Race

Indexed keywords

CELECOXIB; NAPROXEN; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HISPANIC; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIDDLE AGED; NAUSEA; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VERY ELDERLY; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX;

EID: 84901341989     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S61297     Document Type: Article

References (41)

1. United States Census Bureau. US census bureau projections show a slower growing, older, more diverse nation a half century from now. US Department of Commerce. Available from: https://www.census.gov/newsroom/releases/archives/population/cb12-243.html. Accessed October 22, 2013.
2. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26-35.
3. Centers for Disease Control and Prevention. Prevalence of doctor-diagnosed arthritis-attributable effects among Hispanic adults, by Hispanic subgroup-United States, 2002, 2003, 2006, and 2009. MMWR Morb Mortal Wkly Rep. 2011;60(6):167-171.
4. Centers for Disease Control and Prevention. Racial/ethnic differences in the prevalence and impact of doctor-diagnosed arthritis-United States, 2002. MMWR Morb Mortal Wkly Rep. 2005;54(5):119-123.
5. Losina E, Walensky RP, Reichmann WM, et al. Impact of obesity and knee osteoarthritis on morbidity and mortality in older Americans. Ann Intern Med. 2011;154(4):217-226.
6. Chacon JG, Gonzalez NE, Veliz A, et al. Effect of knee osteoarthritis on the perception of quality of life in Venezuelan patients. Arthritis Rheum. 2004;51(3):377-382.
7. 2008 National Population Projections; 1970, 1980, 1990 and 2000 Decennial Censuses. US Census Bureau. Available from: http://www.census.gov/prod/2011pubs/12statab/pop.pdf. Accessed March 7, 2013.
8. Dunlop DD, Song J, Manheim LM, Chang RW. Racial disparities in joint replacement use among older adults. Med Care. 2003;41(2):288-298.
9. Herman CJ, Dente JM, Allen P, Hunt WC. Ethnic differences in the use of complementary and alternative therapies among adults with osteoarthritis. Prev Chronic Dis. 2006;3(3):A80.
10. Olson JC, Foland J. Tracking racial and ethnic disparities of knee replacement rates in Connecticut. Conn Med. 2005;69(4):211-215.
11. Skinner J, Weinstein JN, Sporer SM, Wennberg JE. Racial, ethnic, and geographic disparities in rates of knee arthroplasty among Medicare patients. N Engl J Med. 2003;349(14):1350-1359.
12. Suarez-Almazor ME, Souchek J, Kelly PA, et al. Ethnic variation in knee replacement: patient preferences or uninformed disparity? Arch Intern Med. 2005;165(10):1117-1124.
13. Dominick KL, Bosworth HB, Jeffreys AS, Grambow SC, Oddone EZ, Horner RD. Racial/ethnic variations in non-steroidal anti-inflammatory drug (NSAID) use among patients with osteoarthritis. Pharmacoepidemiol Drug Saf. 2004;13(10):683-694.
14. Celebrex [US prescribing information]. New York, NY, USA: Pfizer Inc.; 2013.
15. Niculescu L, Li C, Huang J, Mallen S. Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs. Curr Med Res Opin. 2009;25(3):729-740.
16. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29(8): 1039-1049.
17. Essex MN, O'Connell M, Bhadra BP. Response to nonsteroidal anti-inflammatory drugs in African Americans with osteoarthritis of the knee. J Int Med Res. 2012;40(6):2251-2266.
18. Ehrich EW, Davies GM, Watson DJ, Bolognese JA, Seidenberg BC, Bellamy N. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol. 2000;27(11):2635-2641.
19. Wendler D, Kington R, Madans J, et al. Are racial and ethnic minorities less willing to participate in health research? PLoS Med. 2006;3(2):e19.
20. Shavers VL, Lynch CF, Burmeister LF. Factors that influence African-Americans' willingness to participate in medical research studies. Cancer. 2001;91(Suppl 1):233-236.
21. Rochon PA, Mashari A, Cohen A, et al. The inclusion of minority groups in clinical trials: problems of under representation and under reporting of data. Account Res. 2004;11(3-4):215-223.
22. Hussain-Gambles M, Atkin K, Leese B. Why ethnic minority groups are under-represented in clinical trials: a review of the literature. Health Soc Care Community. 2004;12(5):382-388.
23. Bartlett C, Doyal L, Ebrahim S, et al. The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess. 2005;9(38):iii-iv, ix-x, 1-152.
24. Cronstein BN. Pharmacogenetics in the rheumatic diseases. Bull NYU Hosp Jt Dis. 2006;64(1-2):16-19.
25. Asanuma Y, Xie HG, Stein CM. Pharmacogenetics and rheumatology: molecular mechanisms contributing to variability in drug response. Arthritis Rheum. 2005;52(5):1349-1359.
26. Bensen WG, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc. 1999;74(11):1095-1105.
27. Kivitz AJ, Moskowitz RW, Woods E, et al. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res. 2001;29(6):467-479.
28. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol. 2001;30(1):11-18.
29. Cooper-DeHoff RM, Zhou Q, Gaxiola E, et al. Influence of Hispanic ethnicity on blood pressure control and cardiovascular outcomes in women with CAD and hypertension: findings from INVEST. J Womens Health (Larchmt). 2007;16(5):632-640.
30. Cooper-DeHoff RM, Aranda JM Jr, Gaxiola E, et al. Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients-findings from the International Verapamil SR/Trandolapril Study (INVEST). Am Heart J. 2006;151(5):1072-1079.
31. Lieu TA, Lozano P, Finkelstein JA, et al. Racial/ethnic variation in asthma status and management practices among children in managed medicaid. Pediatrics. 2002;109(5):857-865.
32. Herholz H, Goff DC, Ramsey DJ, et al. Women and Mexican Americans receive fewer cardiovascular drugs following myocardial infarction than men and non-Hispanic whites: the Corpus Christi Heart Project, 1988-1990. J Clin Epidemiol. 1996;49(3):279-287.
33. Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med. 1994;330(11):763-768.
34. Harris KM, Edlund MJ, Larson S. Racial and ethnic differences in the mental health problems and use of mental health care. Med Care. 2005;43(8):775-784.
35. Pletcher MJ, Kertesz SG, Kohn MA, Gonzales R. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA. 2008;299(1):70-78.
36. Hahn BA. Children's health: racial and ethnic differences in the use of prescription medications. Pediatrics. 1995;95(5):727-732.
37. Xu KT, Rojas-Fernandez CH. Ancillary community pharmacy services provided to older people in a largely rural and ethnically diverse region: a survey of consumers in West Texas. J Rural Health. 2003;19(1): 79-86.
38. Reyes C, Van de Putte L, Falcón AP, Levy RA. Genes, culture, and medicines: bridging gaps in treatment for Hispanic Americans. Natioanal Alliance for Hispanic Health and the National Pharmaceutical Council. Available from: http://www.hispanichealth.org/assets/resource_library/hispanic_report04.pdf. Accessed October 28, 2013.
39. Burroughs VJ, Maxey RW, Levy RA. Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. J Natl Med Assoc. 2002;94(Suppl 10):1-26.
40. Huang SM, Temple R. Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther. 2008;84(3):287-294.
41. Grissinger M. Cultural diversity and medication safety. P&T Community. Available from: http://www.ptcommunity.com/ptJournal/fulltext/32/9/PTJ3209471.pdf. Accessed April 22, 2014.